参芪扶正注射液联合含铂双药化疗治疗晚期非小细胞肺癌的疗效评价  

Efficacy of Shenqi Fuzheng injection combined with platinum-based dual-drug chemotherapy for advanced nonsmall-cell lung cancer

作　　者：李玮[1] 杨永丽 胡佳佳 周彩存[1] LI Wei;YANG Yong-li;HU Jia-jia;ZHOU Cai-cun(Department of Oncology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China;Medical Center,Linkdoc Technology Co.Lted.,Beijing 100083,China)

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433 [2]零氪科技(北京)有限公司医学部,北京100083

出　　处：《中国医院药学杂志》2022年第3期299-303,共5页Chinese Journal of Hospital Pharmacy

基　　金：广东省重点领域研发计划“岭南中医药现代化”重点专项资助(编号:2020B1111110001)。

摘　　要：目的:评价在真实世界中参芪扶正注射液联合含铂双药化疗治疗晚期非小细胞肺癌的疗效和安全性。方法:基于LinkDoc数据库纳入2012—2018年确诊为晚期(ⅢB/Ⅳ期)非小细胞肺癌的患者1128例。采用倾向性评分匹配的方法均衡2组的基线信息,比较2组间的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)及不良事件和化疗相关不良反应的发生率。结果:按照1∶1匹配,最终纳入试验组和对照组各399例。试验组ORR(29.3%vs.25.1%,P=0.176)和DCR(66.9%vs.59.6%,P=0.033)均高于对照组,且试验组中位PFS略高于对照组(7.4个月vs.7.0个月,P=0.861)。试验组化疗完成率高于对照组(74.3%vs.54.6%,P=0.002)。试验组总化疗相关ADR的发生率略高于对照组(66.2%vs.61.4%,P=0.162)。结论:参芪扶正注射液可以提高患者对含铂双药化疗的耐受性,更有利于足量足疗程地完成标准化疗,且总体较为安全,不增加化疗的不良反应发生率,在减少胃肠道反应、保护肝肾功能方面略有优势。OBJECTIVE To evaluate the efficacy and safety of Shenqi Fuzheng injection combined with platinum-containing dual-drug chemotherapy in the treatment of advanced non-small-cell lung cancer(NSCLC)in the real world.METHODS Totally 1128 patients with advanced(ⅢB/Ⅳ)NSCLC were enrolled from2012 to 2018from LinkDoc database.The baseline information of the two groups was balanced by the method of propensity score matching(PSM).The objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS)and the incidences of adverse events and chemotherapyrelated adverse reactions(ADRs)were compared between the two groups.RESULTS According to 1∶1 matching,399 cases in each group were included in the experimental group and the control group.The ORR(29.3%vs.25.1%,P=0.176)and DCR(66.9%vs.59.6%,P=0.033)of the experimental group were higher than those of the control group,and the median PFS of the experimental group was slightly longer than that of the control group(7.4 months vs.7.0months,P=0.861).The completion rate of chemotherapy in the experimental group was higher than that in the control group(74.3%vs.54.6%).The incidence of total chemotherapy-related ADRs in the experimental group was slightly higher than that in the control group(66.2%vs.61.4%,P=0.162).CONCLUSION Shenqi Fuzheng injection can improve the tolerance of platinum-containing dual-drug chemotherapy,so as to better complete standard chemotherapy,and it does not increase the incidence of ADRs during chemotherapy,and has a slight advantage in reducing gastrointestinal reaction and protecting liver and kidney functions.

关 键 词：非小细胞肺癌 化疗 参芪扶正注射液 回顾性研究 

分 类 号：R734.1[医药卫生—肿瘤]